Charts
20 Apr, 2024
19 Apr, 2024
18 Apr, 2024
17 Apr, 2024
16 Apr, 2024
15 Apr, 2024
12 Apr, 2024
11:48
Seeking Alpha
11 Apr, 2024
10 Apr, 2024
News
17 Apr, 2024
13:35
Yahoo! Finance
The heavy selling pressure might have exhausted for Corvus (CRVS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
09 Apr, 2024
Gainers
Jaguar Health (NASDAQ:JAGX) shares rose 25.3% to $0.11 during Tuesday's after-market session. The company's market cap stands ...
20:01
Yahoo! Finance
Atopic dermatitis is the first immune disease indication being studied in the clinic for soquelitinib, the Company’s selective ITK inhibitor Corvus anticipates releasing initial clinical data from trial before year-end 2024 BURLINGAME, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced the initiation of the Company’s randomized, double-blind, placebo-controlled Phase 1 clinical trial evaluating soque
01 Apr, 2024
Corvus (CRVS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
22 Mar, 2024
Corvus (CRVS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
21 Mar, 2024
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q4 2023 Earnings Call Transcript March 19, 2024 Corvus Pharmaceuticals, Inc. reports earnings inline with expectations. Reported EPS is $-0.14 EPS, expectations were $-0.14. CRVS isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon everyone. […]
20 Mar, 2024
Q4 2023 Corvus Pharmaceuticals Inc Earnings Call
InvestorPlace - Stock Market News, Stock Advice & Trading Tips
CRVS stock results show that Corvus Pharma missed analyst estimates for earnings per share the fourth quarter of 2023.
The post CRVS Stock Earnings: Corvus Pharma Misses EPS for Q4 2023 appeared first on InvestorPlace.
More From InvestorPlace
The #1 AI Investment Might Be This Company You’ve Never Heard Of
“America’s Top Trader” Issues A.I. Code Red: Act Now or Miss Out
It doesn’t matter if you have $500 or $5 million. Do this now.
19 Mar, 2024
20:02
Yahoo! Finance
Figure 1 Waterfall Plot for Patients in the 200 mg Dose Cohort of the Soquelitinib Phase 1/1b Clinical Trial for Peripheral T Cell Lymphoma. The plot shows the best percent change in tumor volume in the 21 evaluable patients (eligible patient population), as of January 22, 2024, that were measurable by CT scan or by Modified Severity-Weighted Assessment Tool (mSWAT) for patients with cutaneous involvement. Figure 2 Swimmer Plot of Eligible Patient Population Demonstrating Response and Time on Th
Companies Reporting Before The Bell
• Tencent Music Enter Gr (NYSE:TME) is projected to report quarterly earnings at $0.14 per ...
18 Mar, 2024
Corvus Pharma (NASDAQ:CRVS) is set to give its latest quarterly earnings report on Tuesday, 2024-03-19. Here's what investors need to ...
13 Mar, 2024
20:02
Yahoo! Finance
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PTBURLINGAME, Calif., March 13, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on March 19, 2024 at 4:30 pm ET (1:30 pm PT) to provide a business update and report fourth quarter and full year 2023 financial results. The conference call can be accessed by dialing 1-877-407-0784 (toll-free do
09 Mar, 2024
13:53
Yahoo! Finance
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
12 Feb, 2024
13:30
Yahoo! Finance
Poster presentation unveils Corvus’ next-generation ITK inhibitor candidates designed to deliver precise T cell modulation for immunology indications Figure 1 Venn diagram illustrating different biological properties of the next-gen ITK inhibitors in T cell differentiation assays. BURLINGAME, Calif., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that preclinical data for soquelitinib, the Company’s lead
09 Feb, 2024
Gainers
NanoString Technologies (NASDAQ:NSTG) stock moved upwards by 26.9% to $0.15 during Friday's pre-market session. The company's ...
08 Feb, 2024
Gainers
Xilio Therapeutics (NASDAQ:XLO) shares rose 10.5% to $0.66 during Thursday's after-market session. The market value of their ...
21:05
Yahoo! Finance
Company on track to initiate soquelitinib Phase 3 registrational clinical trial in PTCLBURLINGAME, Calif., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation for soquelitinib for the treatment of T cell lymphoma. Soquelitinib, the Company’s lead ITK inhibitor candidate, is expected to advance into a Phase 3 registrational clinica
06 Feb, 2024
BURLINGAME, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced the appointment of Jeffrey Arcara as Chief Business Officer. Mr. Arcara, who is a proven leader with more than 30 years of commercial experience in the biopharmaceutical industry, will be responsible for leading corporate strategy, business development, portfolio strategy, and new product planning. “Corvus is leading the development of ITK
23 Jan, 2024
BURLINGAME, Calif., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, is deeply saddened to announce the passing of Edith P. Mitchell, M.D., a valued member of the Board of Directors. The Company extends its condolences to her family, colleagues and community. “Edith had a distinguished career in healthcare, spanning patient care, education, clinical research and improving health equity,” said Richard A. Miller, M.D., co-fo
05 Jan, 2024
10:12
Yahoo! Finance
Key Insights Corvus Pharmaceuticals' significant individual investors ownership suggests that the key decisions are...
12 Dec, 2023
11 Dec, 2023
Corvus (CRVS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
12:59
FinancialContent
Shares of Green Giant Inc. (NASDAQ: GGE) fell sharply in pre-market trading after announcing a proposed public offering.
Green ...
09 Dec, 2023
17:00
Yahoo! Finance
Figure 1: Waterfall Plot for Patients in the 200 mg Dose Cohort of the Soquelitinib Phase 1/1b Clinical Trial for Peripheral T Cell Lymphoma. The plot shows the best percent change in tumor volume in the 21 evaluable patients (eligible patient population) that were measurable by CT scan or by mSWAT for patients with cutaneous involvement. Figure 2: Swimmer Plot of Eligible Patient Population (N=21 evaluable, blue) and Ineligible Patient Population (N=11 evaluable, gray). Tumor histologies are al
07 Dec, 2023
Here is how Corvus Pharmaceuticals (CRVS) and Cue Biopharma, Inc. (CUE) have performed compared to their sector so far this year.
21 Nov, 2023
Here is how Corvus Pharmaceuticals (CRVS) and Journey Medical Corporation (DERM) have performed compared to their sector so far this year.
08 Nov, 2023
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q3 2023 Earnings Call Transcript November 7, 2023 Corvus Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0.12, expectations were $-0.16. Operator: Good afternoon, ladies and gentlemen. Thank you for standing by, and welcome to the Corvus Pharmaceuticals Third Quarter 2023 Business Update and Financial Results Conference Call. At this time, […]
Q3 2023 Corvus Pharmaceuticals Inc Earnings Call
07 Nov, 2023
06 Nov, 2023
Corvus Pharma (NASDAQ:CRVS) is set to give its latest quarterly earnings report on Tuesday, 2023-11-07. Here's what investors need to ...
07 Sep, 2023
17:19
FinancialContent
Gainers
American Rebel Holdings, Inc. (NASDAQ: AREB) shares jumped 100% to $1.7909 after the company's subsidiary Champion ...
06 Sep, 2023
Gainers
Artelo Biosciences (NASDAQ:ARTL) shares rose 44.2% to $3.39 during Wednesday's after-market session. Artelo Biosciences's ...
18 Aug, 2023
18:23
FinancialContent
Oppenheimerhas initiated coverage onCorvus Pharmaceuticals Inc(NASDAQ: CRVS) with an Outperform rating and ...
09 Aug, 2023
08 Aug, 2023
07 Aug, 2023
01 Aug, 2023
10 Jul, 2023
16:34
FinancialContent
Gainers
Mobilicom Limited (NASDAQ: MOB) shares jumped 81.3% to $2.7187 after the company announced it received a commercial scale ...
16 Jun, 2023
Over the past 3 months, 4 analysts have published their opinion on Corvus Pharma (NASDAQ:CRVS) stock. These analysts are typically ...
15 Jun, 2023
Gainers
SCWorx (NASDAQ:WORX) stock moved upwards by 128.8% to $0.5 during Thursday's regular session. As of 13:30 EST, this security is ...
17:12
FinancialContent
Gainers
SCWorx Corp. (NASDAQ: WORX) shares jumped 281% to $0.8396.
EdtechX Holdings Acquisition Corp. II (NASDAQ: EDTX) shares ...
02 Jun, 2023
Various names in the biotech sector are seeing a substantial increase in search activity today. Such names include the likes of Akebia Therapeautics, Corvus Pharmaceuticals, and Mirati Therapeutics.
31 May, 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips
When it comes to penny stocks to buy now, be aware of the risks. While some of these little guys can rocket, some will be duds.
The post 3 High-Potential Penny Stocks to Buy Now appeared first on InvestorPlace.
More From InvestorPlace
Buy This $5 Stock BEFORE This Apple Project Goes Live
The Best $1 Investment You Can Make Today
Wall Street Titan: Here’s My #1 Stock for 2023
It doesn’t matter if you have $500 or $5 million. Do this now.
17 May, 2023
Gainers
Immutep (NASDAQ:IMMP) stock rose 141.2% to $3.83 during Wednesday's regular session. Immutep's stock is trading at a volume of ...
16:51
FinancialContent
Gainers
Smart for Life, Inc. (NASDAQ: SMFL) shares climbed 86.2% to $4.32. Smart for Life announced Wednesday that it had ...
15 May, 2023
17:45
FinancialContent
Gainers
NeoGames S.A. (NASDAQ: NGMS) shares climbed 113.3% to $27.38 as the company agreed to be acquired by Aristocrat Leisure ...
12 May, 2023
10 May, 2023
In its Q1 earnings release,Corvus Pharmaceuticals Inc(NASDAQ: CRVS) revealed updated data from the Phase 1/1b trial ...
09 May, 2023
08 May, 2023
07 May, 2023
04 May, 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Most of the biggest biotech stocks on the market started off as unknown penny stocks. Here are seven hot ones to consider.
The post 7 High-Potential Penny Stocks in the Biotech Sector appeared first on InvestorPlace.
More From InvestorPlace
Buy This $5 Stock BEFORE This Apple Project Goes Live
The Best $1 Investment You Can Make Today
Wall Street Titan: Here’s My #1 Stock for 2023
It doesn’t matter if you have $500 or $5 million. Do this now.
05 Apr, 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips
While risky, here are some of the best biotech stocks under $1, with solid catalysts, investors may want to consider.
The post The 3 Best Biotech Stocks Under $1 to Buy for April appeared first on InvestorPlace.
More From InvestorPlace
Buy This $5 Stock BEFORE This Apple Project Goes Live
The Best $1 Investment You Can Make Today
It doesn’t matter if you have $500 or $5 million. Do this now.
Massive Bear Market “Divergence Event” Ahead… And The #1 Way to Play It
04 Apr, 2023
Gainers
Bullfrog AI Hldgs (NASDAQ:BFRG) shares increased by 29.2% to $6.06 during Tuesday's regular session. Trading volume for this ...
29 Mar, 2023
28 Mar, 2023
27 Mar, 2023
Corvus Pharmaceuticals (NASDAQ:CRVS) is set to give its latest quarterly earnings report on Tuesday, 2023-03-28. Here's what investors ...
21 Feb, 2023
Corvus Pharmaceuticals Inc(NASDAQ: CRVS) announcednew data demonstratingthe potential of CPI-818, an ITK inhibitor, ...
Gainers
Chemomab Therapeutics (NASDAQ:CMMB) shares moved upwards by 35.7% to $2.66 during Tuesday's pre-market session. The market ...
21 Dec, 2022
14:17
FinancialContent
The Dow Jones settled higher on Tuesday after recording losses for four straight sessions. Investors, meanwhile, focused on some notable ...
16 Dec, 2022
12:58
FinancialContent
The Dow Jones closed lower by over 700 points on Thursday. Investors, meanwhile, focused on some notable insider trades.
When ...
13 Dec, 2022
17:14
FinancialContent
Gainers
OpGen, Inc. (NASDAQ: OPGN) shares surged 220% to $0.3994 after the company announced topline data from its Unyvero urinary ...
06 Nov, 2022
03 Nov, 2022
02 Nov, 2022
Corvus Pharmaceuticals (NASDAQ:CRVS) is set to give its latest quarterly earnings report on Thursday, 2022-11-03. Here's what investors ...
07 Oct, 2022
Upgrades
For Federal Signal Corp (NYSE:FSS), DA Davidson upgraded the previous rating of Neutral to Buy. In the second quarter, ...
05 Oct, 2022
In this article, we will be taking a look at some of the top stocks in the portfolio of Jeffrey Diehl.
27 Sep, 2022
12:51
FinancialContent
The China National Medical Products Administrationsigned offCorvus Pharmaceuticals Inc's(NASDAQ: CRVS) IND ...
26 Sep, 2022
09 Aug, 2022
Corvus Pharmaceuticals (NASDAQ:CRVS) reported its Q2 earnings results on Monday, August 8, 2022 at 04:05 PM.
Here's ...
08 Aug, 2022
05 Aug, 2022
28 Jun, 2022
08:23
FinancialContent
Gainers
Evofem Biosciences, Inc. (NASDAQ: EVFM) shares jumped 187.7% to close at $1.07 on Monday amid the Supreme Court ...
27 Jun, 2022
Gainers
USA Truck, Inc. (NASDAQ: USAK) shares climbed 112.6% to close at $31.00 on Friday. DB Schenker and USA Truck announced ...
10 May, 2022
Investors in Corvus Pharmaceuticals Inc (CRVS) saw new options become available this week, for the June 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the CRVS options chain for the new June 17th contracts and identified the following put contract of particular interest.
05 May, 2022
20 Apr, 2022
On Wednesday, 160 companies hit new 52-week lows.
Areas of Significance In Today's 52-Week Lows:
Walt Disney ...
11 Mar, 2022
10 Mar, 2022
Corvus Pharmaceuticals (NASDAQ:CRVS) reported its Q4 earnings results on Thursday, March 10, 2022 at 04:00 PM.
Here's what ...
Companies Reporting Before The Bell
• Despegar.com (NYSE:DESP) is expected to report quarterly loss at $0.08 per share ...
09 Mar, 2022
Corvus Pharmaceuticals (NASDAQ:CRVS) is set to give its latest quarterly earnings report on Thursday, 2022-03-10. Here's what investors ...
06 Mar, 2022
15:02
The Week Ahead In Biotech (March 6-12): Quiet Week On Tap With Earnings Season Reaching It Final Leg
FinancialContent
Biotech stocks reversed course in the week endingMarch 4, as the Ukrainian crisis weighed down on the broader market as well as ...
14 Jan, 2022
13:07
FinancialContent
Here's a roundup of top developments in the biotech space over the last 24 hours.
Stocks In Focus
Corvus Says Chinese Angel ...
17 Dec, 2021
Gainers
GBS (NASDAQ:GBS) stock rose 14.28% to $1.44 during Friday's after-market session. At the close, GBS's ...
01 Dec, 2021
Gainers
Ardelyx (NASDAQ:ARDX) stock increased by 19.29% to $1.36 during Wednesday's pre-market session. The market ...
10 Nov, 2021
13:19
FinancialContent
Here's a roundup of top developments in the biotech space over the last 24 hours.
Stocks In Focus
MorphoSys COO To Leave To ...
08 Nov, 2021
13:24
FinancialContent
Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week.
What was good ...
30 Oct, 2021
18:47
FinancialContent
Fosun Pharma announced a $628 million deal to acquire a 73% stake in Chengdu Antejin Biotech, a vaccine company. Fosun paid $174 million to nine Antejin shareholders and it contributed its own subsidiary, Dalian Aleph Biomedical, for the remainder.
